{"product_id":"9783319380674","title":"Resistance to Targeted Anti-Cancer Therapeutics","description":"\u003ch1\u003eResistance to Targeted Anti-Cancer Therapeutics\u003c\/h1\u003e \u003ch2\u003eBonavida, Benjamin; Chouaib, Salem\u003c\/h2\u003e \u003cp\u003eThis comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.\u003c\/p\u003e \u003ch3\u003eDetails\u003c\/h3\u003e \u003cp\u003ePublished by: Springer\u003c\/p\u003e \u003cp\u003ePublication Date: 2016-10-17\u003c\/p\u003e \u003cp\u003eFormat: Paperback\u003c\/p\u003e \u003cp\u003eISBN-13: 9783319380674\u003c\/p\u003e \u003cp\u003eDOI: 10.1007\/978-3-319-17807-3\u003c\/p\u003e \u003cp\u003eDimensions: 235cm x155cm\u003c\/p\u003e \u003cp\u003ePages: 353\u003c\/p\u003e ","brand":"Springer International Publishing","offers":[{"title":"Default Title","offer_id":44395441160332,"sku":"9783319380674","price":98.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0710\/9545\/1788\/files\/9783319380674.jpg?v=1770822005","url":"https:\/\/fh90cf-fv.myshopify.com\/products\/9783319380674","provider":"Late Knight Books and Services, LLC","version":"1.0","type":"link"}